Nivalis Therapeutics, Inc. releases salary data. CEO sees compensation fall -39%

Nivalis Therapeutics, Inc. just filed its annual proxy statement, which details the salary information of its key executives. In 2016, the company's CEO made 2,075,775.

The table is included below:

Name
Year Salary
($)(1)
Bonus
($)(2)
Stock
Awards
($)(3)
Option
Awards
($)(4)
Nonequity
Incentive Plan
Compensation
($)(5)
All Other
Compensation
($)(6)
Total ($)

Jon Congleton(7)

2016 $ 450,000 — — $ 1,348,250 $ 225,000 $ 52,525 $ 2,075,775

2015 375,000 — — 2,792,832 206,397 42,750 3,416,979

David Rodman(7)


2016

318,750

200,000

168,999

883,474

180,000

7,950

1,759,173

Janice Troha


2016

383,835

—

—

593,230

134,342

7,950

1,119,357

2015 363,825 — — 1,164,776 175,826 7,950 1,712,377

2014 363,825 50,000 — — — 7,800 421,625

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Nivalis Therapeutics, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Securities to be offered to employees in employee benefit plans - June 21, 2018
Departure of Directors or Certain - June 14, 2018
Nivalis Therapeutics, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - June 11, 2018
Entry into a Material Definitive - June 11, 2018

Auto Refresh

Feedback